Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)

Inclusion Criteria:

* Patient older than 18 years.
* Performance status ≤ 2 according to the WHO criteria.
* Life expectancy\> 3 months.
* Patient in hormonal blockade based on surgical castration by orchiectomy or pulpectomy, medical or agonist or antagonists of LHRH associated or not with anti-androgens or any other treatment that blocks the fraction of non-gonadal testosterone, resulting in a testosterone \<0.5 ng / mL.
* Patient with adenocarcinoma of the prostate and histologically proven metastatic castration-resistant stage, defined by: objective progression of at least one measurable tumor target and / or assessable by RECIST, and / or increase in PSA ("rising PSA").
* Satisfactory biological functions (renal, hepatic and hematologic)
* Patient who signed the consent for participation before entering the study.
* Affiliation to a social security scheme (or be the beneficiary of such a plan) under the terms of the law of 9 August 2004.

Exclusion Criteria:

* Age \<18 years.
* Performance status\> 2 according to the WHO criteria.
* Patient deprived of liberty or under guardianship, patient with (the) condition (s) psychological, family, social or geographic may interfere with the proper conduct of the study.
* Diagnosis of a second malignancy in the past 5 years, with the exception of a basal cell skin cancer considered cured.
* Patient with brain metastases at initial assessment.
* Patient with another pathology deemed incompatible with the inclusion in the protocol.
* Laboratory tests inadequate.
* History of malabsorption syndrome or extensive resection of the upper digestive tract.
* Uncontrolled intercurrent infection.
* Pathology autoimmune and / or chronic active inflammation.
* peripheral neuropathy grade 2 according to the criteria of the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4.0).
* History of allergy to polysorbate 80.
* Treatment with nonsteroidal anti-inflammatory and / or cyclooxygenase-2 dated within three weeks.
* Concomitant with a drug test or participation in another clinical trial within \<30 days treatment.
* Regular Taking dietary supplements.